- Home
- TGS vs MANE Comparison
TGS vs MANE Comparison
Compare TGS & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TGS | MANE |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.3B |
| IPO Year | 2002 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TGS | MANE |
|---|---|---|
| Price | $26.70 | $117.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $40.00 | ★ $83.33 |
| AVG Volume (30 Days) | 207.0K | ★ 604.3K |
| Earning Date | 05-12-2026 | 03-30-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.01 | $36.26 |
| 52 Week High | $36.35 | $131.24 |
Technical Indicators
Market Signals| Indicator | TGS | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 64.38 |
| Support Level | N/A | $92.62 |
| Resistance Level | $31.88 | $130.52 |
| Average True Range (ATR) | 0.82 | 5.86 |
| MACD | -0.28 | 2.09 |
| Stochastic Oscillator | 6.95 | 82.65 |
Price Performance
Historical ComparisonAbout TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a natural gas transporter in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Liquids Production and Commercialization. It generates maximum revenue from the Natural Gas Transportation segment. Geographically, it derives the majority of its revenue from Argentina.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.